Clinical trials: Thyroid Eye Disease, TED

Thyroid Eye Disease (TED)

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

• Active, not recruiting
• Age: 18 to 75 years
• Phase 3

This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).

Trial name

NCT06812325

Testing

VRDN-003

Where

64 sites in United States, France and 5 more

Volunteers

320 people

Sponsor

Viridian Therapeutics, Inc.